BridgeMD
New treatment option for Heart Failure
Official title Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
ClinicalTrials.gov ID: NCT04983823
What this study is testing
- What it's testing
- This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old. The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.
- Time commitment: about 24 months
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 85. Healthy volunteers may be eligible.
You may be able to join if
- History of COVID-19 infection
- Live within a geographically accessible area for follow-up
You likely can't join if
- Valvular stenosis or regurgitation of \>moderate severity
- History of previous heart failure (baseline New York Heart Association (NYHA) classification \>2)
- Inability to acquire interpretable images (identified from baseline echo)
- Contraindications to beta blockers or angiotensin-converting enzyme inhibitors
- Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief...
- Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both.
See the full eligibility criteria
- History of COVID-19 infection
- Live within a geographically accessible area for follow-up
- Valvular stenosis or regurgitation of \>moderate severity
- History of previous heart failure (baseline New York Heart Association (NYHA) classification \>2)
- Inability to acquire interpretable images (identified from baseline echo)
- Contraindications to beta blockers or angiotensin-converting enzyme inhibitors
- Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to...
- Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both.
- Mobility impairment that would impact participants' ability to perform exercise
- Unable to provide written informed consent to participate in this study
The study team makes the final eligibility decision.
Where it's taking place
- Melbourne, Victoria, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 24 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 85 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Melbourne, Victoria, Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.